AxoGen (AXGN) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
Axogen, Inc. Reports 2019 First Quarter Financial Results
May 8, 2019 4:03 PM EDTFirst Quarter Revenue of $23.3 million, representing 35% growth versus first quarter 2018
ALACHUA, Fla., May 08, 2019 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today reported financial results and business highlights for the first quarter ended March 31, 2019.
First Quarter 2019 Financial Results and Recent Business Highlights
Revenue of $23.3 million, an increase of 35% compared to first quarter 2018 revenue of $17.3 million Gross margin of 84.0% compared to 84.3% in the... More


